Heteroarylacetamide inhibitors of factor Xa

Compounds of formula (I)

• Rd—C(O)—N(Re)—Rc—CH2—C(O)—N(Ra)(Rb) (I)
• wherein
• Ra is a member selected from the group consisting of hydrogen and C1-6 alkyl;
• R1 is Rb1-Rb2;
• wherein Rb1 is a member selected from the group consisting of aryl and heteroaryl, said aryl and heteroaryl being optionally substituted by one or more substituents independently selected from the group consisting of C1-6 alkyl and halogen;
• wherein Rb2 is a member selected from the group consisting of aryl, heteroaryl and heterocyclyl, said aryl, heteroaryl and heterocyclyl being optionally substituted by one or more substituents independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, halogen, cyano, nitro, amino, mono- or di-C1-6 alkyl substituted amino, hydroxy, hydroxy C1-6 alkyl, aminocarbonyl, mono- or di-C1-6 alkyl substituted aminocarbonyl, halo C1-6 alkyl, C1-6 alkylsulfonyl, C1-6 alkylsulfinyl, C1-6 alkylthio, amino C1-6 alkyl, mono- or di-C1-6 alkyl substituted amino C1-6 alkyl, aminosulfonyl, and mono- or di-C1-6 alkyl substituted amino sulfonyl, wherein one or two carbon atoms of said aryl, heteroaryl and heterocyclyl can optionally be replaced with a carbonyl group;
• or wherein
• Ra and Rb, together with the nitrogen atom to which they are attached, form heterocyclyl-A-Rb3, wherein said heterocyclyl can optionally be substituted by a member selected from the group consisting of halogen and C1-6 alkyl;
• wherein A is a member selected from the group consisting of a bond, —O— and C1-6 alkylene wherein one —CH2— of said C1-6 alkylene can optionally be replaced with a carbonyl group, and another —CH2— of said C1-6 alkylene can optionally be replaced with —NRf—;
• wherein Rb3 is a member selected from the group consisting of amino optionally mono- or di-substituted by a substituent independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl, aryl, heteroaryl, C3-7 cycloalkyl and heterocyclyl, said aryl, heteroaryl, C3-7 cycloalkyl and heterocyclyl being optionally substituted by one or more substituents independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, halogen, cyano, nitro, amino, mono- or di-C1-6 alkyl substituted amino, hydroxy, hydroxy C1-6 alkyl, aminocarbonyl, mono- or di-C1-6 alkyl substituted aminocarbonyl, halo C1-6 alkyl, C1-6 alkylsulfonyl, C1-6 alkylsulfinyl, C1-6 alkylthio, amino C1-6 alkyl, mono- or di-C1-6 alkyl substituted amino C1-6 alkyl, aminosulfonyl and mono- or di-C1-6 alkyl substituted amino sulfonyl, wherein one or two carbon atoms of said aryl, heteroaryl, C3-7 cycloalkyl and heterocyclyl can optionally be replaced with a carbonyl group;
• wherein Rc is heteroaryl optionally substituted by one or more substituents independently selected from the group consisting of halogen and C1-6 alkyl and one or two carbon atoms of said heteroaryl being optionally replaced with a carbonyl group;
• wherein Rd is aryl, heteroaryl or heterocyclyl, said aryl, heteroaryl and heterocyclyl optionally being substituted by one or more substituents independently selected from the group consisting of halogen, C1-6 alkyl and C1-6 alkoxy, and the aryl may be fused to a heterocyclyl ring;
• wherein Re is hydrogen or C1-6 alkyl;
• wherein Rf is hydrogen or C1-6 alkyl;
• and prodrugs and pharmaceutically acceptable salts thereof.